TPH2 and breast cancer: In particular, the observed increased breast-cancer risk in TPH2 variant carriers may result from modified brain melatonin levels due to a dysfunctional SCN (together with reduced melatonin levels in the retina) that upon light-at-night periods may reduce pineal melatonin secretion.